Studies immune cells in people with advanced chronic kidney disease
Observes immune T cells from blood samples in adults with end-stage kidney disease.
Plain-language title generated from the registry record
Registry title: Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
Key facts
- Where
- Orléans, FranceSee the site
Where in France
- Center Hospitalier Universitaire d'OrléansOrléans, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Régional d'Orléans
- Trial code
- NCT06474169
- Record updated
- 25 June 2026
- Original description
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.Read full original descriptionShow less
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.
The study population was patients with chronic kidney disease.
Inclusion: Male or female ≥ 18 years; Informed participants who did not object to participating in the study.
Exclusion: Prior organ transplantation (including bone marrow transplantation); Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion; Chronic progressive infections; Participant under guardianship, curatorship or deprived of liberty; Pregnant or breastfeeding women.